Jennifer E. Miller (@millerbioethics) 's Twitter Profile
Jennifer E. Miller

@millerbioethics

Associate Professor @YaleMed Founder @BioethicsIntl @GoodPharmaScoreCard #Bioethics #DataEthics #pharmaethics #pharmaesg

ID: 34388092

linkhttps://medicine.yale.edu/profile/jennifer_e_miller/ calendar_today22-04-2009 20:32:47

3,3K Tweet

2,2K Followers

2,2K Following

I. Glenn Cohen (@cohenprof) 's Twitter Profile Photo

Spoke to The Pulse (Grant Hill) about AI-powered mental health chatbots,their promise & some perils from a legal/bioethics perspective. You can listen to the episode whyy.org/segments/the-f… and read my paper w/ Julian De Freitas Nature Medicine on topic nature.com/articles/s4159…

Holly Fernandez Lynch (@hollylynchez) 's Twitter Profile Photo

A bill I can get behind - making it easier to pay clinical trial participants while avoiding legal concerns and impact on public benefits. 1/ statnews.com/2024/08/27/cli…

Jennifer E. Miller (@millerbioethics) 's Twitter Profile Photo

FDA scolds Abbvie for misleading Ad for migraine med. Marketing claims don’t match clinical trial findings statnews.com/pharmalot/2024…

Jennifer E. Miller (@millerbioethics) 's Twitter Profile Photo

Med societies need #ethics guidance for Docs selling practices to #privateequity firms, argues Peter Ubel Guidelines should limit price hikes & out-of-network charges & highlight ethical tradeoffs of a potential sale. Totally agree guidance is needed! jamanetwork.com/journals/jama-…

Jennifer E. Miller (@millerbioethics) 's Twitter Profile Photo

CVS is exploring a break-up of its retail & insurance units. It’s unclear where their #pbm would go. uk.finance.yahoo.com/news/exclusive…

Yale CRRIT (@yale_crrit) 's Twitter Profile Photo

Do pharmaceutical manufacturers, when launching products in new therapeutic classes, strategically pay the same physicians who the first-in-class competitor marketed to? Physicians beware! Our analysis in JAMA by Wilton Sun & Joseph Ross suggests yes. (1/5) Thread 🪡🧵

Do pharmaceutical manufacturers, when launching products in new therapeutic classes, strategically pay the same physicians who the first-in-class competitor marketed to?

Physicians beware! Our analysis in <a href="/JAMA/">JAMA</a> by Wilton Sun &amp; <a href="/jsross119/">Joseph Ross</a> suggests yes.

(1/5) Thread 🪡🧵
Harlan Krumholz (@hmkyale) 's Twitter Profile Photo

🚨 NEW in JACC Journals: Despite global initiatives, 2° prevention medication use in CVD stagnant or declining in most income-level groups. 12-year study across 17 countries. We must do better! 📉💔#HealthEquity American College of Cardiology #PURE Read the full study 👉 jacc.org/doi/10.1016/j.…

🚨 NEW in <a href="/JACCJournals/">JACC Journals</a>: Despite global initiatives, 2° prevention medication use in CVD stagnant or declining in most income-level groups. 12-year study across 17 countries. We must do better! 📉💔#HealthEquity <a href="/ACCinTouch/">American College of Cardiology</a> #PURE

Read the full study 👉 jacc.org/doi/10.1016/j.…